- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
4.88
+0.11(+2.31%)
Closed·
After Hours
4.97+0.09(+1.84%)
·
Fair Value
An estimate of a Y mAbs Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.70
4.96
52 wk Range
3.55
16.11
YMAB Financial Summary
A brief financial summary of Y mAbs Therapeutics as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 34.9 | 65.27 | 84.82 | 87.69 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 32.38 | 57.7 | 73.4 | 72.43 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -115.43 | -83.32 | -21.19 | -25.11 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -55.28 | -95.57 | -21.43 | -29.67 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 212.78 | 141.46 | 127.87 | 119.9 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 27.88 | 28.28 | 20.13 | 23.7 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 180.11 | 109.22 | 100.99 | 92 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -58.6 | -28.3 | -14.03 | 4.44 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -102.56 | -75.92 | -27.23 | -15.71 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 61.04 | - | - | - | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 108.31 | 0.08 | 0.1 | 4.31 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 66.93 | -75.8 | -27.13 | -11.4 | |
* In Millions of USD (except for per share items)
Analyst Ratings
8 Buy
0 Hold
2 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.70
(+201.23% Upside)
FAQ
What were Y mAbs Therapeutics's earnings for the latest quarter?
The Y mAbs Therapeutics EPS (TTM) is -0.63. Y mAbs Therapeutics reported sales of 20.90, net income of -5.20, and EPS of -0.12 for the latest quarter.
What was Y mAbs Therapeutics's net income for the latest quarter?
Y mAbs Therapeutics's net income for the latest quarter was -5.20.
How did Y mAbs Therapeutics's performance compare year-over-year in the latest quarter?
The company's revenue moved from 26.50 in the previous quarter to 20.90 in the latest quarter, and net income moved from -6.79 to -5.20 compared to the previous quarter.
What is Y mAbs Therapeutics's net profit margin on a TTM basis?
Y mAbs Therapeutics's trailing twelve months (TTM) net profit margin is -33.83%.
How does Y mAbs Therapeutics's debt to equity ratio compare to industry standards?
Y mAbs Therapeutics's total debt-to-equity ratio is 0.67%.
What is Y mAbs Therapeutics's return on investment on a TTM basis?
Y mAbs Therapeutics's trailing twelve months (TTM) return on investment (ROI) is -29.93%.
Did Y mAbs Therapeutics gain or lose cash last quarter?
In the latest quarter, Y mAbs Therapeutics's net change in cash was -6.92 million.
What were Y mAbs Therapeutics's total assets and liabilities in the latest quarter?
As of the latest quarter, Y mAbs Therapeutics reported total assets of 112.61 million and total liabilities of 18.96 million.
How has Y mAbs Therapeutics's total revenue grown this year?
Y mAbs Therapeutics's total revenue was 26.50 in the previous quarter and 20.90 in the latest quarter.
What is Y mAbs Therapeutics's gross margin on a TTM basis?
Y mAbs Therapeutics's trailing twelve months (TTM) gross margin is 81.83%.
What was Y mAbs Therapeutics's revenue per share for the latest quarter?
Y mAbs Therapeutics's revenue per share for the latest quarter was 44.33.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.